A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
Condition(s):Ischemic StrokeLast Updated:January 22, 2016Completed
Hide Studies Not Open or Pending
Condition(s):Ischemic StrokeLast Updated:January 22, 2016Completed
Condition(s):Calcium Phosphate Kidney StonesLast Updated:October 13, 2023Recruiting
Condition(s):Post-Ischemic StrokeLast Updated:June 7, 2018Completed
Condition(s):Depressive Disorder, MajorLast Updated:February 25, 2020Completed
Condition(s):Multiple SclerosisLast Updated:September 5, 2013Completed
Condition(s):Multiple SclerosisLast Updated:March 6, 2019Completed
Condition(s):Moderate-severe PainLast Updated:September 25, 2018Terminated
Condition(s):Heart FailureLast Updated:March 19, 2024Recruiting
Condition(s):Chronic Stable AnginaLast Updated:April 3, 2018Unknown status
Condition(s):Alzheimer’s DiseaseLast Updated:September 5, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.